Clinical Trial Update: Supraphysiological Androgen to Enhance Treatment Activity in Metastatic Castration-Resistant Prostate Cancer, SPECTRA Study [Phase 2]

View source ↗

Summary

A Phase 2 clinical trial (SPECTRA) is evaluating whether supraphysiological androgen can enhance treatment activity in metastatic castration-resistant prostate …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Castration-resistant Prostate Cancer
• Prostate Cancer

Drugs mentioned

• Supraphysiological Androgen

Snippet

Sponsor: University of Washington | Conditions: Castration-Resistant Prostate Carcinoma, Metastatic Prostate Adenocarcinoma | Phase 2 | Status: RECRUITING